Molecular Partners AG filed a Form 6-K with the SEC on October 29, 2026, furnishing unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2026, along with a press release issued the same date.

Key Highlights

  • Net loss of CHF 38,410 thousand for the nine months ended September 30, 2026, compared with CHF 49,002 thousand in the same period of 2025, according to the filing.
  • Zero revenues from research and development collaborations were reported for both the nine-month and three-month periods ended September 30, 2026 and 2025.
  • Cash and cash equivalents of CHF 57,493 thousand as of September 30, 2026, down from CHF 82,653 thousand at January 1, 2026.
  • Total shareholders' equity fell to CHF 50,662 thousand at September 30, 2026, from CHF 80,334 thousand at January 1, 2026.
  • Basic and diluted net loss per share of CHF (1.01) for the nine months ended September 30, 2026, versus CHF (1.32) in the comparable prior-year period.
  • Net cash used in operating activities was CHF 35,541 thousand for the nine months ended September 30, 2026, compared with CHF 40,106 thousand in the same period of 2025.
  • Pension remeasurement gain of CHF 6,078 thousand was recorded in other comprehensive result for the nine-month period, partially offsetting the net loss in total comprehensive result.

Molecular Partners Financial Position and Operating Results Through September 30, 2026

According to the filing, Molecular Partners AG reported a net result attributable to shareholders of CHF (38,410) thousand for the nine months ended September 30, 2026, an improvement from CHF (49,002) thousand recorded in the corresponding period of 2025. For the three months ended September 30, 2026, the company reported a net result of CHF (11,708) thousand, compared with CHF (11,836) thousand in the prior-year quarter. The company disclosed no revenues from research and development collaborations in either period.

The filing shows total operating expenses of CHF 39,093 thousand for the nine months ended September 30, 2026, comprised of research and development expenses of CHF 27,331 thousand and selling, general and administrative expenses of CHF 11,762 thousand. No restructuring expenses were recorded in the 2026 nine-month period, whereas CHF 2,733 thousand in restructuring expenses were reported in the comparable 2025 period. Total assets as of September 30, 2026, stood at CHF 64,515 thousand, down from CHF 102,107 thousand at December 31, 2025, with the decline driven primarily by a reduction in cash and cash equivalents and the maturation of short-term time deposits.

The company's cumulative losses reached CHF 344,072 thousand as of September 30, 2026, up from CHF 311,753 thousand at January 1, 2026. Share-based compensation costs of CHF 2,784 thousand were recognized during the nine-month period. The filing states that the interim financial statements were approved for issuance by the Audit and Finance Committee on October 26, 2026. Molecular Partners AG describes itself as "a clinical-stage biopharmaceutical company pioneering designed ankyrin repeat proteins (DARPin) candidates to treat serious diseases, with a current focus on oncology and virology." The company's shares are listed on the SIX Swiss Exchange and on the Nasdaq Global Select Market, both under the ticker MOLN. The Nasdaq listing is referenced in the filing under NASDAQ:MOLN.

What Was Disclosed

Molecular Partners AG furnished unaudited interim financial statements for the nine and three months ended September 30, 2026, reporting a nine-month net loss of CHF 38,410 thousand, no collaboration revenues, and cash of CHF 57,493 thousand at period end.